Products Affected - Description
Atropine Sulfate ophthalmic solution, Akorn
1%, 2 mL bottle, 1 count (NDC 17478-0215-02)
1%, 5 mL bottle, 1 count (NDC 17478-0215-05)
1%, 15 mL bottle, 1 count (NDC 17478-0215-15)
Reason for the Shortage
- Alcon has discontinued Isopto Atropine.
- Akorn received FDA approval for atropine sulfate 1% ophthalmic solution in July 2014; this new product launched in January 2015.
- Sandoz has discontinued atropine sulfate ophthalmic solution.
- Valeant discontinued their atropine sulfate 1% ophthalmic solution products in 2015.
There is insufficient supply for usual ordering.
Estimated Resupply Dates
Akorn has atropine sulfate ophthalmic solution in 2 mL, 5 mL, and 15 mL bottles available in limited supply.
November 6, September 7, July 20, April 25, March 3, January 28 and 6, 2016; December 22 and 11, September 9, July 20, June 16 and 1, April 20 and 6, February 26 and 4, January 21 and 7, 2015; December 15 and 3, November 21, 2014, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins